Prostate cancer incidence among finasteride and alpha-blocker users in the finnish prostate cancer screening trial

British Journal of Cancer

Volumn 101, Issue 5, 2009, Pages 843-848

  Murtola, T J ^a,b   Tammela, T L J ^c,d   Maattanen L ^e   Ala Opas, M ^f   Stenman, U H ^g   Auvinen, A ^a  

^a UNIVERSITY OF TAMPERE   (Finland)

^b Central Hospital of Middle Finland   (Finland)

^c TAMPERE UNIVERSITY HOSPITAL   (Finland)

^d TAMPERE UNIVERSITY OF TECHNOLOGY   (Finland)

^e FINNISH CANCER REGISTRY   (Finland)

^f HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

^g UNIVERSITY OF HELSINKI   (Finland)

Author keywords

Alpha blockers; Benign prostatic hyperplasia; Epidemiology; Finasteride; Prostatic neoplasms; Screening

Indexed keywords

ALFUZOSIN; FINASTERIDE; PROSTATE SPECIFIC ANTIGEN; TAMSULOSIN;

ADULT; AGED; ARTICLE; BODY MASS; CANCER DIAGNOSIS; CANCER GRADING; CANCER INCIDENCE; CANCER PATIENT; CANCER RISK; CANCER SCREENING; CANCER STAGING; CLINICAL EVALUATION; CONTROLLED STUDY; DRUG USE; FAMILY HISTORY; GLEASON SCORE; HUMAN; MAJOR CLINICAL STUDY; MALE; OBSERVATIONAL STUDY; ORGAN SIZE; PRESCRIPTION; PREVALENCE; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATE HYPERTROPHY; REIMBURSEMENT; TREATMENT DURATION;

ADRENERGIC ALPHA-ANTAGONISTS; AGED; COHORT STUDIES; DATA INTERPRETATION, STATISTICAL; FINASTERIDE; FINLAND; FOLLOW-UP STUDIES; HUMANS; INCIDENCE; MALE; MASS SCREENING; MIDDLE AGED; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; RISK FACTORS; TIME FACTORS;

EID: 70249109675     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/sj.bjc.6605188     Document Type: Article

References (19)

1. Benning CM, Kyprianou N (2002) Quinazoline-derived alpha1-adrenoceptor antagonists induce prostate cancer cell apoptosis via an alpha1-adrenoceptor- independent action. Cancer Res 62: 597-602
2. Crawford ED (2003) Epidemiology of prostate cancer. Urology 62: 3-12
3. Etzioni RD, Howlader N, Shaw PA, Ankerst DP, Penson DF, Goodman PJ, Thompson IM (2005) Long-term effects of finasteride on prostate specific antigen levels: results from the prostate cancer prevention trial. J Urol 174: 877-881
4. Finnish Medical Society Duodecim. Current Care Summaries: Benign Prostatic Hyperplasia (in Finnish). Available at: http://www.kaypahoito.fi. Accessed February 26th, 2009
5. Harris AM, Warner BW, Wilson JM, Becker A, Rowland RG, Conner W, Lane M, Kimbler K, Durbin EB, Baron AT, Kyprianou N (2007) Effect of a1-adrenoceptor antagonist exposure on prostate cancer incidence: an observational cohort study. J Urol 178: 2176-2180
6. Irani J, Ravery V, Pariente JL, Chartier-Kastler E, Lechevallier E, Soulie M, Chautard D, Coloby P, Fontaine E, Bladou F, Desgrandchamps F, Haillot O (2002) Effect of nonsteroidal anti-inflammatory agents and finasteride on prostate cancer risk. J Urol 168: 1985-1988
7. Ishizuka O, Nishizawa O, Hirao Y, Ohshima S (2002) Evidence-based meta-analysis of pharmacotherapy for benign prostatic hypertrophy. Int J Urol 9: 607-612
8. Kyprianou N, Benning CM (2000) Suppression of human prostate cancer cell growth by alpha1-adrenoceptor antagonists doxazosin and terazosin via induction of apoptosis. Cancer Res 60: 4550-4555
9. Lucia MS, Epstein JI, Goodman PJ, Darke AK, Reuter VE, Civantos F, Tangen CM, Parnes HL, Lippman SM, La Rosa FG, Kattan MW, Crawford ED, Ford LG, Coltman Jr CA, Thompson IM (2007) Finasteride and high-grade prostate cancer in the Prostate Cancer Prevention Trial. J Natl Cancer Inst 99: 1375-1383
10. Määttänen L, Auvinen A, Stenman UH, Rannikko S, Tammela T, Aro J, Juusela H, Hakama M (1999) European randomized study of screening for prostate cancer: first-year results of the Finnish trial. Br J Cancer 79: 1210-1214
11. Marberger M (2006) Drug insight: 5alpha-reductase inhibitors for the treatment of benign prostatic hyperplasia. Nat Clin Pract Urol 3: 495-503
12. Martikainen J, Rajaniemi S (2002) Drug Reimbursement Systems in EU Member States, Iceland and Norway. The Social Insurance Institution, Finland, Social Security and Health Reports 54. Available at: http://www.kela.fi/in/internet/ liite.nsf/ABID/030303101726PN/$File/Drug-reimbursement.pdf?openElement. Accessed February 26th, 2009
13. Merrill RM, Wiggins CL (2002) Incidental detection of population-based prostate cancer incidence rates through transurethral resection of the prostate. Urol Oncol 7: 213-219
14. Murtola TJ, Tammela TL, Määttänen L, Hakama M, Auvinen A (2007) Prostate cancer risk among users of finasteride and alpha-blockers-a population-based case-control study. Eur J Cancer 43: 775-781 (Pubitemid 46502907)
15. Pinsky P, Parnes H, Ford L (2008) Estimating rates of true high-grade disease in the prostate cancer prevention trial. Cancer Prev Res (Phila Pa) 1: 182-186
16. Roehrborn CG, Bruskewitz R, Nickel JC, McConnell JD, Saltzman B, Gittelman MC, Malek GH, Gottesman JE, Suryawanshi S, Drisko J, Meehan A, Waldstreicher J, Proscar Long-Term Efficacy and Safety Study Group (2004) Sustained decrease in incidence of acute urinary retention and surgery with finasteride for 6 years in men with benign prostatic hyperplasia. J Urol 171: 1194-1198 Statistics Finland. Finland in Figures: Population Structure. Available at: http://www.stat.fi/til/vaerak/index-en.html. Accessed February 26th, 2009
17. Teppo L, Pukkala E, Lehtonen M (1994) Data quality and quality control of a population-based cancer registry. Acta Oncol 33: 365-369
18. Thompson IM, Chi C, Ankerst DP, Goodman PJ, Tangen CM, Lippman SM, Lucia MS, Parnes HL, Coltman Jr CA (2006) Effect of finasteride on sensitivity of PSA for detecting prostate cancer. J Natl Cancer Inst 98: 1128-1133
19. Thompson IM, Goodman PJ, Tangen CM, Lucia MS, Miller GJ, Ford LG, Lieber MM, Cespedes RD, Atkins JN, Lippman SM, Carlin SM, Ryan A, Szczepanek CM, Crowley JJ, Coltman Jr CA (2003) The influence of finasteride on the development of prostate cancer. N Engl J Med 349: 215-224